Every dollar amount and date on this page is quoted from the official settlement document.
BioXcel Therapeutics $9.75M Class Action Settlement
Court case: Hills et al. v. BioXcel Therapeutics, Inc., et al.
BioXcel Therapeutics agreed to a $9,750,000 settlement resolving a securities class action alleging the company misled investors between March and June 2023. Eligible investors who purchased BioXcel common stock during that window could recover roughly $1.52 per share before deductions. The claim filing window closed June 30, 2026.
Official eligibility wordingInvestors who purchased or otherwise acquired BioXcel Therapeutics Inc. common stock between March 9, 2023, and June 28, 2023. Checked against the official settlement source by SettleSignal on June 19, 2026.
Key facts
- Who may qualify The settlement covered investors who purchased or otherwise acquired BioXcel Therapeutics common stock between March 9, 2023, and June 28, 2023.
- Estimated payoutApproximately $1.52 per share before deductions from a $9,750,000 settlement fund
- Claim deadlineJune 30, 2026 (closed)
- Proof requiredYes
- What you needThe claim deadline (June 30, 2026) has passed, and the settlement is no longer accepting new claims.
- CourtUnited States District Court for the District of Connecticut
Important dates
What you'll need to file
From our inspection of the official claim form:
- Filing method Online or mail-in
- Notice ID Not needed
- Documentation Required to upload proof of transactions/holdings (broker trade confirmations and/or monthly brokerage statements). File upload is mandatory for online filing. Representative Filers must submit transactions in an electr…
How hard is this claim to file?
What the form asks
- — Your SSN (individuals) or EIN/TIN (entities) (Your tax documents or brokerage account records)
- — Number of BioXcel common shares you held at the end of trading the day before the class period began (Brokerage account statement for March 8, 2023)
- — Date of each buy or sell transaction during the class period (Broker confirmation slips or account statements)
- — Share quantity for each individual transaction (Broker confirmation slip for each trade)
- — Per-share price and total dollar value for each transaction (Broker confirmation slip for each trade)
- — Number of BioXcel common shares you held at end of trading on the last day of the class period (Brokerage account statement for June 28, 2023)
Documents you'll need
Watch out for
- All joint purchasers must sign the claim form — a missing co-owner signature can void the claim.
- Executors, administrators, guardians, conservators, and trustees must attach proof of authority when filing on behalf of others.
- Shares bought and sold entirely before June 29, 2023, have a recognized loss of zero and will generate no payout.
- Class members whose calculated payment falls below a minimum threshold will not receive a payout.
- Payout is pro rata and depends on the total number of valid claims submitted — actual recovery may be higher or lower than the estimated average.
We prepare — you file on the official site yourself. This is not legal advice and is not an eligibility decision; the administrator and court decide.
Verify it yourself
How we verified this record
- Claim deadline
- Payout details
- Eligibility
- Proof requirement
- Administrator
- Official claim link
- Payment status
- 1 field queued for re-check
1 official source linked to this record.
-
Claim deadline
June 30, 2026
-
Eligibility summary Quoted in the official eligibility wording above ↑
-
Proof requirement
Yes
-
Payment status
Claim period open
-
Estimated payout
Approximately $1.52 per share before deductions from a $9,750,000 settlement fund
-
Administrator
Strategic Claims Services
Show all 7 more verified fields
-
Official claim URL
bioxcelsecuritiessettlement.com
-
Objection deadline
August 5, 2026
-
Opt-out deadline
August 5, 2026
-
Class period start
March 9, 2023
-
Class period end
June 28, 2023
-
Court
United States District Court for the District of Connecticut
-
Case name
Hills et al. v. BioXcel Therapeutics, Inc., et al.
Where to act
Status history
- Claim deadline passed.
- Settlement published after verification.
- Verified field details updated from an official source.
